BRM’s data on Environmental Pertubation funded via SBIR grants will be featured in a plenary session at the ADA’s 66th Scientific Session scheduled to convene in Washington, D.C. June 9th to the 13th. The symposia is titled “Nature vs. Nurture in Type I Diabetes”. This is a follow on to last year’s BRM abstract entitled “Maternal Immunization Protects Weanling LEW.1WR1 Rats from Virus-Induced Diabetes”, which was selected for oral presentation at the ADA’s 65th session held in San Diego, California.
Worcester Telegram & Gazette – April 4- 2006 – Biomedical Research Models, Inc. has received a one year Small Business Innovation Research grant of $295,807 from the National Institute of Allergy and Infectious Disease for work on a vaccine against herpes simplex virus type 2, the company reported. The government health institute is also recommending that BRM receive an additional $287,298 next year for a second year of work on the vaccine. BRM is a privately held life science company. HSV-2 is the virus most often responsible for genital herpes. BRM’s DNA vaccine and a follow-up booster immunization are designed to raise an immune response against disease-causing agents. The company plans to test the vaccine first in mice.
Biomedical Research Models Inc. signed a five year contract with the National Institutes of Diabetes Digestive and Kidney Diseases (NIDDK) totaling $4,889,031. The objectives of this contract are to assist NIDDK in development of potential new therapies for the prevention of Type 1 diabetes. The contract was competitively awarded after BRM responded to RFP-NIDDK-05-05 entiltled: Preclinical Studies of Efficacy in Animal Models of Type 1 diabetes. Working closely with the government’s T-1 RAID project officer, BRM scientific staff along with consultants and collaborators at the Pioneer Valley Life Science Initiative will begin assessing novel therapies on behalf of the government for entry into Trial-Net.
The creation of this National Research Center to be based in Worcester and Springfield, MA is part of the Congressionally established Diabetes Research Working Groups Strategic plan to Cure Diabetes in the 21st Century.
BRM competed nationally for two T-1 RAID contracts. It was selected as the semifinalist in January for both contracts. The first contract was awarded in May to the University of California at San Diego. UCSD is ranked #13 nationally for USPHS-NIH funding. BRM a company that is ranked in the top 25% of the 3,181 institutions that received USPHS funding in 2004 out-competed another Top 25 research institution based in California for this contract.
Neuralstem, Inc. announced today the execution of an exclusive license agreement to Biomedical Research Models, Inc. for the development of Neuralstem compounds to treat certain cognitive and neurological impacts of diabetes.
PRNewswire-FirstCall — Neuralstem, Inc. (OTC Bulletin Board: NRLS), headquartered here, announced today the execution of an exclusive license agreement to Biomedical Research Models, Inc. for the development of Neuralstem compounds to treat certain cognitive and neurological impacts of diabetes.
The agreement includes annual license fees until product commercialization; milestone payments upon the completion of agreed-upon clinical goals, which could total approximately $38 million for each licensed product that is approved by the FDA; as well as royalties on ensuing products.
The license covers a library of Neuralstem patent-pending compounds, discovered using Neuralstem’s patented human neural stem cells. The company said that the compounds, when orally administered, have been shown in adult mice to recruit and stimulate the body’s own stem cells to form new neurons in the brain, and may be useful in healing and protecting injured brain areas.
“What we have is a true platform technology,” said Richard Garr, Neuralstem President and Chief Executive Officer. “Neuralstem’s ability to grow regionally specific, physiologically relevant human nerve cells in large quantities, in vitro (in dishes) provides a unique tool for discovering drugs to treat neurological and psychiatric diseases. It gives the company a way to leverage our cells’ unique properties in both our cell therapy and drug development programs. Our licensee, Biomedical Research Models, Inc., is focused on developing novel drug therapies for the treatment of diabetes, and will provide an excellent partner to move the results of our drug discovery program forward in this area.”
Neuralstem recently received a $500,000 grant from the NIH to study the possible effectiveness of its compounds to treat depression. “The creation of Neuralstem’s unique drug discovery platform (patent-pending) was funded by an award from the U.S. Department of Defense several years ago,” Garr added. “Neuralstem retains the rights to these compounds for all indications other than diabetes.”